A new antimalarial drug candidate, discovered through a longstanding collaboration between WEHI and global biopharmaceutical company MSD has entered Phase 1 clinical testing in healthy participants.

Scientists from Drexel University’s College of Medicine and Columbia University’s Irving Medical Center have uncovered a crucial structural feature of a key malaria drug target, known as PfATP4, and ...

Poor-quality and fake antimalarial drugs are leading to drug resistance and inadequate treatment that is endangering global efforts made to control and eliminate malaria over the past 10 years, ...

Structural insights into a potent antimalarial drug candidate's interaction with the malaria parasite Plasmodium falciparum have paved the way for drug-resistant malaria therapies, according to a new ...

Most people with lupus take an antimalarial drug to control their symptoms. These drugs may also prevent blood clots and damage to your organs from lupus. Antimalarials are mostly safe to use and ...

Tabitha Mwangi does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

Researchers led by teams at the University of California, Riverside (UCR), the University of California, Irvine, and the Yale School of Medicine have developed a compound that they found to be ...